NOV 14, 2022 3:00 AM PST

Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial

WRITTEN BY: Katie Kokolus

About 20% of breast cancers exhibit elevated levels of a protein known as HER2.  You may have heard the classifier “HER2-positive” breast cancer, which refers to these cases.  HER2 status remains a paradoxical factor in breast cancer diagnosis.  While HER2-positive cancer cells grow quickly and aggressively, HER2 can also serve as a therapeutic target, increasing the likelihood of a HER2-positive breast cancer patient responding to treatment. 

A monoclonal antibody called trastuzumab remains highly effective in treating HER2-positive breast cancer patients.  When trastuzumab binds to HER2 on cancer cells, it inhibits cell growth.  Some patients successfully treated with trastuzumab develop HER2-specific immunity, which confers a favorable prognosis, including extended progression-free and overall survival.  Studies have demonstrated that HER2-specific T cells also play a role in protecting patients from breast cancer recurrence

Unfortunately, trastuzumab does not induce HER2-specific immunity in all patients.  To develop a method to increase the number of breast cancer patients developing beneficial HER2-specific immunity, and the accompanying good prognosis, a team of researchers investigated the efficacy of a plasmid DNA vaccine encoding for part of the HER2 protein.  The researchers recently published their findings in JAMA Oncology

The investigators carried out a phase 1 clinical trial (NCT00436254) to assess potential toxicities associated with vaccination.  The study included 66 patients diagnosed with stage III or IV HER2-positive breast cancer, and the researchers compared three doses of DNA vaccine (22 patients received each dose).  In addition to evaluating for toxicity, the investigators measured immunity associated with vaccine treatment by examining the immune cells circulating in the blood. 

Patients received three doses of the vaccine along with an adjuvant called granulocyte-macrophage colony-stimulating factor (GMCSF).  The investigators observed no severe toxicities associated with treatment.  Participants most often reported injection site reactions (82%) as an adverse event, but smaller percentages of patients experienced flulike symptoms (33%) and fatigue (36%).  Notably, the study included ten years of follow-up, so the researchers ruled out long-term adverse events associated with the vaccine. 

When measuring measured HER2-specific immunity, the researchers found that higher doses of vaccine demonstrated better immune responses than the patients receiving the lowest dose.  The authors conclude that their findings demonstrate that this HER2 DNA vaccine induces immunity.  The research team has begun a phase 2 randomized clinical trial (NCT05163223). 

 

Sources: Cancer Res, JAMA Oncol (Datta), JAMA Oncol (Disis)

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
JUL 28, 2022
Cancer
Potential Marker for Prostate Cancer Prognosis Identified
JUL 28, 2022
Potential Marker for Prostate Cancer Prognosis Identified
Cytokines, proteins that affect the immune system, can elicit their effects in either a beneficial or an inhibitory capa ...
SEP 12, 2022
Cancer
Novel Method to Detect Cancer with a Blood Screen Demonstrates Feasibility
SEP 12, 2022
Novel Method to Detect Cancer with a Blood Screen Demonstrates Feasibility
Early detection of cancer benefits patients with almost all cancer types.  Late-stage tumors remain more difficult ...
SEP 27, 2022
Clinical & Molecular DX
New Research Elucidates the Mechanism of Skin Cancer Metastasis to the Brain and Points to Groundbreaking Treatment
SEP 27, 2022
New Research Elucidates the Mechanism of Skin Cancer Metastasis to the Brain and Points to Groundbreaking Treatment
In advanced stages of skin cancer, patients develop brain metastases about 90% of the time. Though this is one of the mo ...
NOV 07, 2022
Cancer
Compound Produced by Pomegranates Could Help Fight Cancer
NOV 07, 2022
Compound Produced by Pomegranates Could Help Fight Cancer
Since ancient times, scientific and anecdotal evidence has noted many health benefits associated with pomegranates prope ...
NOV 23, 2022
Cannabis Sciences
Why researchers have hope that cannabis may help fight ovarian cancer
NOV 23, 2022
Why researchers have hope that cannabis may help fight ovarian cancer
There's a positive, growing link between cannabis and the fight against ovarian cancer. Here's why researchers are optim ...
NOV 28, 2022
Drug Discovery & Development
Construction of the New US-Based Center for Bioprocessing
NOV 28, 2022
Construction of the New US-Based Center for Bioprocessing
Sino Biological is pleased to announce the signing of a lease with Hines and initiation of construction on its new Cente ...
Loading Comments...